The Latest Breaking News from Alzheimer Disease

Swiss pharmaceutical firm carried out two identical phase 3 trials of gantenerumab, with about 1,000 volunteers in each

Alzheimer's disease is a progressive disorder that causes brain cells to waste away and die. Alzheimer's disease is the most common cause of dementia, which is a term used to describe a group of symptoms that affect memory, thinking and social abilities severely enough to interfere with daily function.

In 1906, Alois Alzheimer, a psychiatrist and neuroanatomist, reported “a peculiar severe disease process of the cerebral cortex” to a gathering of psychiatrists in Tübingen, Germany. The case was a 50-year-old woman who suffered from memory loss, delusions, hallucinations, aggression and confusion – all of which worsened until her untimely…

People who are prescribed the drug will need regular MRI scans to check for brain swelling or bleeding

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer's disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical decline of people with Alzheimer's disease by 27% compared with a placebo after 18 months of treatment.

FORT WORTH, Texas — The National Institutes of Health is giving $149 million to researchers at the University of North Texas Health Science Center to pay for researchers to study the biology of Alzheimer’s disease in multiple racial and ethnic groups.

Experts are still unclear as to whether Covid can trigger the onset of Alzheimer's or speed its development.

Researchers from the Case Western Reserve University in Cleveland, Ohio analysed the electronic health records of 6.2 million adults